very Fresenius And you partnership. Thank quarter news the for afternoon, Chris. thank congratulations And you, everyone. Good of earnings on exciting the call. our joining second
clinical will next readouts on I positive the also our of minutes, with business. I as provide catalysts with list you will For data a to review that believe updates we recent will few our studies. long serve you
staffing front, with To and clinical focus of and lasting around executing progress academic long enrollment. our continue the on pandemic the institutions we the studies, major execute our shifting continue now across the sites, On driving we observe make to impact these are to board the these working the we to getting to now the resources studies participating we're world, studies, first is we in made majority of relating that, executional enrollment. Having phase which by specifically strong sites shifting up the for are phase and have our second in we of Accordingly, running. and execution these of studies, said shortages. the our progress focus
on laser the on these the remain clinical Our next now FDA STAR-T to the It will on priority of two these top teams more driving enrollment studies STAR-D are in studies. studies focused our and come our programs, and slide. both be
is now third our Importantly, programs, the phase readouts and publications. one executing the we're registry on completed centered of CTC data and
business. in that you that area now therapeutic progress by We positive integrated in generating medical Christian earlier. significant are fully made have within our our heard of led are already global affairs verticals from data team efforts also the referenced new support These
Society trial the end Cardio-Thoracic number year already data We're on main original continue shock. clinical failure later on out this year. septic new noted more of the more and coming in in out before of including are of early XX very in August, and to we publications Slide, the Cardiology CytoSorb September with this data papers new presented expect releases liver grow to this in months, the in the European As from for acute new heart including ELSO European the the new a removal within major ECMO next in the few of the meeting antithrombotic seven be with Association with in presentation presentations targeting registry at will initiation also at and two together data Germany that Surgery original data randomized conferences scheduled international results data and at value, with proposition readouts CTC October, of exciting a transplantation with
Next slide, please.
in our both has STAR-T studies the at now least FDA report study sites to shifted now add a startup attention both from activities, activated studies and happy of the focus total both Turning enrollment. driving we STAR-D, open our patients XX activities plan resources are To recruiting our sites have of and sites studies. to to into that operational to to studies
to plan the eligible in For on from agent remaining hot focus regions, mainly STAR-T, add Ticagrelor sites We Ticagrelor. reference on is our acute treatment where Ticagrelor the protocols. helping beds dominant syndrome sites identify patients coronary used
to for we we're the STAR-D, of numbers encouraged see interest reported patients sites. and process, that continue strong high the by or are cardiac still participating surgery early For DOACs although, are in drugs ATR by on the
enrolled. are review have both after XX three are previously with patients pre-specified the studies As being targeting first DSMB one we communicated, milestones safety the
For STAR-T, next the we reached to in this few expect be months. milestone
already, log will help sites strategies us as STAR-D, from progress, we're screening inform data but bit us noted also study drive now still a For on in enrollment. that gain to better the little actively on visibility early process, collecting we're but
please. slide Next
Next is our programs. now to non-FDA
results European previously and noted the in we have final already, been final been are And with submitted on is for registry meeting Society first reporting ongoing. results XX treated the and These results will the next published. the have XXX on ECMO Care patients Medicine CTC presented CytoSorb be now Intensive of readouts data a Interim at also As patients completed upcoming October. publication.
in our study open recruiting trial Next enrolling and process, patients. actively patients The randomized the with of is sites shock. majority actively septic is with now clinical
will project that the are patients milestone of will be analysis the interim triggered that continue We to be after in XXXX. reached XX enrolled
Moving on with in study pilot acute Hep-On-Fire failure. single-arm to the liver patients
now We study in and execution plan such, as early optimize delays to relaunch have it experienced XXXX. options are the exploring of and the we to
registries. international Moving on our to two now
made we and before to additional Luxembourg. enrolling end including also a and Germany targeting we actively COSMOS finally, I'm brisk significant European on now to-date, as will is now in enrollment open the we're Spain, international surgery the has is the at XXXX. to countries registry. countries, rebounds Austria data the it report four registry patients year. expanding progress actively the of be And Based STAR pace And UK, enrolling Our Germany, major in second cardiac that soon country to study. conferences multiple happy anticipate patients enrolling the in and
early readouts the XXXX. enrollment data project in and will COSMOS providing process continue in to be Although pace, the we without yet great visibility the also on still
areas. turn our the indications use of has global with outputs blue. applications. to currently Three this impressive in aggregate shown have light green with to the This are there been data of year inventory papers noted critical positive international been would highlighted in These teams the multiple papers work medical most already I in our care table. upcoming more opinion blue attention are The some the and at long have please. collaboration our six in readouts this have therapeutic are slide as like data kidney and the and shown across already, In technology publications. list conferences publicly produced table. four in and slide new original publications are of liver been this international now of leaders very presentations And and Next renowned on current press. summarizes key prioritized that by clinical are original doing accepted in
prominent shock, of disease that You failure and states, septic span liver ECMO. including use across CytoSorb new with device a this treatment sepsis will of of pancreatitis note and data acute and acute multitude
recently our profound efficient technology We and a demonstrated device, published and analysis removal. have cytokine more also provides between that a comparative and CytoSorb competitive
still in different all now clinical originates and are Finally, peer they're the multiple published available for that here although Germany, listed contributions the we geographies, evidence as online. of from including indexed please India. papers majority have and U.S., France the All journals, note review such
course, to provide these We upon than papers of more are copies happy request. of
mentioned which renowned published Germany, other Canada, U.S., three significant from August. in journal, here market of the analysis from a dataset CytoSorb represent same be pigs none cost the with and trials are summary upcoming applications. the the as again, dataset the you but will the transplantation, has once to in positive we German of incredibly you table. will Cardiology economic in again, green And generated in transplantation been evidence staphylococcus randomized at at Hungary. submitted clinical for it Similar originating that in original the patients in data is that more these in original noted Surgery surgery for light exciting than publications Communications. have early originating previous ranked presented this slide, they're exciting see also presentations been a discussed, cardiovascular contributions will meeting results been papers scientific what have and health new heart Cardio-Thoracic is blue from that randomized of in conferences, please. first And anti-thrombotic an October. Once savings on Nature while in aureus an European see a slide, kind undergoing including from papers additional here entries And highlight in And trial demonstrating for published already Next its this Christian you The the presented the shown In three the clinical already in at have meeting is lung aggregate, Sweden removal, year. original seven with majority study be for purple. very in highly Association of endocarditis. Together European note are Society
is with can value drug risk our and the of for endocarditis removal technology the the evidence so that You and use mounting, surgery. high antithrombotic see benefits
journals lung they're However, represent exciting online. than we're in in and evidence heart about provide are such happy technology. new equally are believe of copies all and growth are excited for available more and we request. we papers to upon our that again, published the new the emerging areas Again, transplantation Once peer-reviewed index
slide Next please.
So now in actively anticipate STAR-D from are Both focus made critical in remain over We activated activities our The Phase programs and sites. drive accelerated sites our the and focus to going progress that will in conclusion, clinical programs our our and enrollment to now start-up X forward have X STAR-T operational are FDA enrollment. shifting enrollment. we Phase with activities priorities. now master XX top shift enrolled
positive Vince? and Our positive and liver with way. Thank Officer COSMOS leading like would and publications to more turn kidney relaunching trial EU programs number finally, other significant this be that, are our President Capponi. of I coming and optimization in on Operating with the markets. And will international our conferences call for process readouts large an in and peer-reviewed cardiovascular XXXX. your at and the create should will hand you for also data tailwinds undergo progressing And Chief critical the Hep-On-Fire, STAR over care Vince attention. to journals
